AL-12182

structure in first source

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	McLaughlin, Marsha A: 2 articles (10/2006 - 09/2004)
2.	Sharif, Najam A: 2 articles (10/2006 - 09/2004)
3.	Williams, Gary W: 2 articles (10/2006 - 09/2004)
4.	Crider, Julie Y: 1 article (10/2006)
5.	Kelly, Curtis R: 1 article (10/2006)
6.	Parker, Janet L: 1 article (10/2006)
7.	Xu, Shouxi: 1 article (10/2006)
8.	Conrow, Raymond E: 1 article (09/2004)
9.	Dean, W Dennis: 1 article (09/2004)
10.	Delgado, Pete: 1 article (09/2004)

1.	Hyperemia 10/01/2006 - "in vivo, AL-12182 elicited dose-related hyperemia in the rabbit eye, miosis in the cat eye, and ocular hypotension in the nonhuman primate eye. " 09/06/2004 - "Topical ocular dosing of AL-12182, the isopropyl ester prodrug of the potent agonist 13, lowered intraocular pressure in the monkey by 40% accompanied by minimal conjunctival hyperemia in the rabbit. "
2.	Miosis 10/01/2006 - "in vivo, AL-12182 elicited dose-related hyperemia in the rabbit eye, miosis in the cat eye, and ocular hypotension in the nonhuman primate eye. "
3.	Ocular Hypotension 10/01/2006 - "in vivo, AL-12182 elicited dose-related hyperemia in the rabbit eye, miosis in the cat eye, and ocular hypotension in the nonhuman primate eye. "